Browse the evidence

Common side effects of all GLP-1-agonists include an increased risk of gastrointestinal and gallbladder-related complaints.

Clinicians should be aware of potential gastrointestinal and gallbladder-related side effects when prescribing GLP-1-agonists.

Anti-obesity vaccines face significant immunological and regulatory challenges.

Understanding these challenges is crucial for developing effective anti-obesity vaccines.

The most common adverse reactions associated with tirzepatide are gastrointestinal disorders.

Healthcare providers should inform patients about potential gastrointestinal side effects when prescribing tirzepatide.

If not detected and treated early, MASLD can progress to fibrosis and hepatocellular carcinoma.

Early detection and treatment of MASLD are crucial to prevent serious complications.

Tirzepatide reverses β-cell dedifferentiation in HFD-fed mice.

Tirzepatide may help restore β-cell function by reversing dedifferentiation in diabetic conditions.

GLP-1 RA-induced gastroparesis can increase the risk of aspiration during ophthalmic surgery.

Surgeons should be aware of the aspiration risk in patients using GLP-1 RAs.

GLP-1R agonists can improve cardiac contractility in human hearts.

Practitioners may consider GLP-1R agonists as a potential treatment to enhance heart contractility.

Epicardial adipose tissue may contribute to arrhythmogenesis through pro-inflammatory and pro-fibrotic effects.

Addressing epicardial adipose tissue may be important in managing arrhythmias in obese patients.

Dietary protein intake did not affect daily myofibrillar protein synthesis rates during immobilization.

Practitioners should note that increasing dietary protein may not mitigate muscle loss during short-term disuse.

Adipositas ist eine multifaktorielle Erkrankung mit global steigender Prävalenz.

Practitioners should recognize the multifactorial nature of obesity when addressing it in patients.

Wash-in and washout effects can threaten the validity of short-term dietary trials.

Researchers should consider the timing of interventions and outcomes in dietary trials to ensure validity.

Type 2 Diabetes Mellitus (T2DM) is characterized by tissue insulin resistance and loss of pancreatic β cell function.

Understanding the nature of T2DM is crucial for effective management strategies.

The term 'prediabetes' does not adequately describe the cellular changes occurring in individuals with dysglycemia.

Awareness of the limitations of the term 'prediabetes' can improve clinical understanding.

Higher BMI was associated with a different airway shape, including larger minimum anteroposterior distance and smaller minimum lateral distance.

Understanding the changes in airway shape with BMI can help tailor OSA treatment strategies.

A better understanding of antidiabetic drugs' effects on skeletal muscle lipid metabolism is needed.

Future research should prioritize understanding how antidiabetic drugs affect lipid metabolism in skeletal muscle.

Obesogenic stimuli promote adipose tissue macrophages to recruit neutrophils from the bone marrow in mice.

Understanding neutrophil recruitment can inform strategies to manage inflammation in obesity.

Inhibiting neutrophil recruitment out of the bone marrow in obese mice or during weight loss reduces bone marrow myelopoiesis and adipose tissue inflammation.

Targeting neutrophil recruitment may help reduce inflammation during obesity management.

In humans with obesity, plasma neutrophil chemokines are increased and correlate with increased insulin resistance, but do not decrease with weight loss.

Monitoring neutrophil chemokines may provide insights into insulin resistance in obese patients.

Nitro-oleic acid (NO2-OA) treatment improves glucose tolerance in high fat diet (HFD)-fed Nrf2fl/fl mice but does not improve glucose tolerance in adipocyte-specific Nrf2 knockout (ANKO) mice.

NO2-OA may be effective for improving glucose tolerance in certain populations but not in those lacking Nrf2 in adipocytes.

Adipocyte-specific deletion of Nrf2 negates the protective effects of nitro-oleic acid on glucose tolerance.

Understanding the role of Nrf2 in adipocytes can inform strategies for managing glucose tolerance in obesity.

Diabetic nephropathy affects approximately 700 million people worldwide and is the leading cause of chronic kidney insufficiency.

Healthcare providers should be aware of the high prevalence of diabetic nephropathy in T2D patients.

Effective nephroprotection requires early identification of at-risk patients through screening.

Implement routine screening for CKD risk factors in clinical practice.

Cheeses improved C. elegans lifespan, mobility with aging, and age-related muscle degradation.

Incorporating these cheeses may support longevity and mobility in aging populations.

MitoQ supplementation did not impact mitochondrial respiration or H2O2 emission in the presence of ADP.

MitoQ does not enhance mitochondrial function during exercise in older adults.